Post hoc analysis of SCORED (type 2 diabetes with kidney disease): higher 2022 HF stage was associated with 2- to 4-fold higher CV death/HF events on placebo; sotagliflozin's benefit was consistent across stages (HR 0.74; Pinteraction=1.00).
Secondary analysisn = 10,584
Odutayo et al. Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled Trial